For some patients, targeted therapy is their best shot. The Molecular Tumor Board at DCI is matching more and more patients to approved therapies and clinical trials.
Wrestling with “next generation sequencing," this Mr. T is helping Duke oncologists utilize a Molecular Tumor Board to deliver patient centered precision cancer medicine.